Twice weekly low dose interferon-beta-1a in relapsing-remitting multiple sclerosis (CROSBI ID 94315)
Prilog u časopisu | stručni rad
Podaci o odgovornosti
Debelić, Diana ; Jurjević, Anton ; Willheim, Ksenija ; Sepčić, Juraj
engleski
Twice weekly low dose interferon-beta-1a in relapsing-remitting multiple sclerosis
We present a randomized open-label study of interferon-beta-1a in 14 patients with relapsing-remitting multiple sclerosis. Interferon-beta-1a was administred in dose of 11 mg subcutaneously twice weekly for 12 months. The main objective of the study was to assess treatment efficacy in comparison with the 12 months pretreatment period. The number of exacerbation decreased in 8, did not change in 3 and increased in 3 patients. There was 9 severe exacerbation in the pretreatment year and only 1 in treatment period. By the end of therapy year disability decreased 0.68 according to Expanded Disability Status Scale outcome measure showing improvement in 1 of the major functional systems affected. Side effects, that were mild, appeared during the first three therapy months. The results suggest that interferon-beta-1a in dose of 11 mg given twice weekly seems effective in reducing disability in relapsing-remitting multiple sclerosis.
interferon-beta; multiple sclerosis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano